643TiP Open-label, phase II study of ladiratuzumab vedotin (LV) for unresectable locally advanced or metastatic solid tumors

Abstract

LIV-1 is a transmembrane protein expressed in a variety of cancer types. SGN-LIV1A, or ladiratuzumab vedotin (LV), is a novel, investigational, intravenous, humanized immunoglobulin G1 antibody-drug conjugate (ADC) directed against LIV-1. LV mediates delivery of monomethyl auristatin E, which drives antitumor activity through cytotoxic cell killing and induces immunogenic cell death. In a phase I study, LV (2.5 mg/kg every 21 days) was well tolerated and demonstrated encouraging efficacy in previously treated patients with metastatic breast cancer (Modi 2017).